



Managing cardiovascular risk in primary care - practical considerations

Saturday 3rd October 2020
9.30am - 11.30am

Webinar

At this event

- Listen to local and national experts in the field
- Enhance your knowledge for protecting patients from the risk of CV events
- Managing patients with chronic arterial disease or symptomatic peripheral arterial disease and Optimising stroke prevention in NVAf
- Receive a certificate for your appraisal portfolio

Bayer medicinal product(s) will be discussed and relevant prescribing information(s) will be available during the webinar

RP-XAR-GB-2416 | Date of Preparation: August 2020 • In conjunction with MediConf, this online event has been organised and fully funded by Bayer

Meet the Speakers ...

Dr Yassir Javaid MA (Cantab) FRCP FRCGP PGDip Cardiology

Cardiovascular and Diabetes Lead Nene CCG
Primary Care Cardiovascular lead, East Midlands Clinical Network
RCGP Clinical Adviser for Cardiology

Dr Javaid qualified from Cambridge University and completed his GP VTS training in Northampton. He has an interest in cardiology and echocardiography and was a clinical lead in the Northamptonshire Community Cardiology service, which had a focus on patients with heart failure and valve disease.

He was named Pulse “GP of the Year” in 2015 for his work in reducing stroke emergency admissions in the East Midlands. He is also a council member of the British Heart Valve Society, accredited member of the British Society of Echocardiography and on the editorial board for the British Journal of Cardiology.



Dr Jim Moore

Dr Moore is a GP and a General Practitioner with Special Interest in Heart Failure in Gloucestershire.

He is president of the Primary Care Cardiovascular Society.

He has maintained an interest in cardiology and cardiovascular disease throughout his medical career, particularly those aspects that are relevant to Primary Care.

He was Clinical Lead for the West of England AHSN “Don’t wait to anticoagulate” project.

He was a member of the NICE Chronic Heart Failure Guideline Committee 2018 and is a current member of the National Heart Failure Audit Domain Expert Group.



Your Learning Agenda ...

Managing cardiovascular risk in primary care - practical considerations

Around 7.4 million people in the UK live with the burden of cardiovascular disease (CVD), making it one of the biggest causes of death and disability.

It costs our health services billions of pounds each year. And after decades of progress in reducing CVD mortality, there has recently been a significant slowdown in improvement.

At this patient case-based webinar you will have the opportunity to look at practical implementation of relevant guidelines on the detection and management of high-risk cardiovascular conditions, with the goal of improving quality of care for patients at risk of CV events.

In response to pressures on the NHS, the way health care professionals deliver anticoagulants may need to change. NHS England has recently published a clinical guide for the management of anticoagulant services during the coronavirus pandemic

<https://www.england.nhs.uk/coronavirus/publication/specialty-guides/>

The clinical guide states switching appropriate patients from warfarin to a DOAC may be considered to avoid regular blood tests for INR monitoring. Whilst DOACs require blood tests to assess renal function throughout treatment - the monitoring is predictable, less rigorous than INR testing with warfarin and is routinely carried out in primary care.

British Heart Foundation Heart Statistics Factsheet UK, December 2019.
 British Heart Foundation.

<https://www.bhf.org.uk/what-we-do/news-from-the-bhf/news-archive/2019/may/heart-and-circulatory-disease-deaths-in-under-75s-see-first-sustained-rise-in-50-years>

This programme will be led by Dr Yassir Javaid and Dr Jim Moore

Your Learning Agenda...

Part 1 – Improving management of cardiovascular disease

- ▶ The burden of CVD and NHS ambitions

Part 2 – Primary prevention of CVD

- ▶ Thrombotic conditions frequently coincide
- ▶ Modifiable and non-modifiable risk factors

Part 3 – Secondary prevention of CVD

Optimising lipid modification therapy

Part 4 – Enhancing vascular protection

- ▶ The burden of chronic coronary disease
- ▶ New approaches to reducing the risk of atherothrombotic events
- ▶ Current vascular protection strategies and current guidelines

Part 5 – Optimising stroke prevention in NVAF

- ▶ Diagnosis and assessment of NVAF
- ▶ The burden of disease and current management approaches
- ▶ 'Detect, protect, perfect'

Part 6 – Patients with NVAF or VTE: Practical considerations for transitioning from warfarin to a DOAC

- ▶ Practical considerations

Programme ...

COURSE CODE 1449

- 9.30am - 10.20am Improving management of cardiovascular disease
 Primary prevention of CVD
 Secondary prevention of CVD
 Enhancing vascular protection
- 10.20am -11.30am Optimising stroke prevention in NVAF
 Patients with NVAF or VTE: Practical considerations for
 transitioning from warfarin to a DOAC
 Q&A

Book online at <https://www.medicconf.co.uk/Event-Details.aspx?id=1398>

WE DO NOT TAKE BOOKINGS OVER THE PHONE

Please note that all confirmations will be sent to you via email ONLY acknowledging your place, candidate registration number and other essential information.

MediConf do not release delegate emails to 3rd parties. Occasionally we may use email addresses to inform you of future events or services provided by our supporting organisations. Facilities are available for you to unsubscribe to this at any time.

The personal data provided by you to register for an event is used to process your booking request and for post event follow up information and feedback. For more information, please refer to our privacy policy which can be found at <https://www.medicconf.co.uk/Profile.aspx> where you may also find further information about processing of personal data and your rights. If you need any further information please contact the Data Processing Manager: Janet Poyner E. janet@medicconf.co.uk

If you register to attend an event, your personal data (name, professional title, work address) will be provided to the meeting sponsor, Bayer plc, who will use your personal data for the purposes of customer relationship management and record-keeping in accordance with compliance requirements. Bayer is an independent data controller of your personal data for these purposes. For more information on how Bayer holds your personal data, please see Bayer's privacy policy at www.bayer.co.uk/en/information-on-data-privacy-for-hcps

For a full list of our booking terms and conditions please visit our website: www.medicconf.co.uk

IF YOU DO NOT RECEIVE YOUR CONFIRMATION WITHIN 48 HOURS please contact the office

**MediConf UK Ltd | 19 Wood Street | Lytham St Annes | Lancashire | FY8 1QR
 T. 01253 712894 | W. www.medicconf.co.uk | E. rebecca@medicconf.co.uk**

Bayer medicinal product(s) will be discussed and relevant prescribing information(s) will be available during the webinar

RP-XAR-GB-2416 | Date of Preparation: August 2020 • In conjunction with MediConf, this online event has been organised and fully funded by Bayer